Actively Recruiting
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Led by Xinqiao Hospital of Chongqing · Updated on 2025-07-14
40
Participants Needed
2
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Investigators intend to combine low-dose hypersensitivity with high-dose immunopotentiation effect, and use super-hyperfractionation pulse radiotherapy, which is expected to achieve the effect of in situ vaccine that can enhance tumor killing, protect normal tissues, reduce immune cell damage and enhance tumor immunogenicity at the same time, and play a stronger immunopotentiation effect in combined immunotherapy. Thereby inducing a stronger abscopal effect of radiotherapy.
CONDITIONS
Official Title
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and able to follow the study protocol
- Diagnosed with stage IIIB or above non-small cell lung cancer confirmed by histopathology
- Tumor mass suitable for stereotactic body radiation therapy, less than 5 cm
- Eligible for immune checkpoint inhibitor therapy according to Chinese Society of Clinical Oncology guidelines
- Age 18 to less than 75 years
- Eastern Cooperative Oncology Group Performance Status Score (ECOG PS) between 0 and 3
You will not qualify if you...
- Poor compliance or violation of study regulations
- Dysfunction of important organs such as recent myocardial infarction, angina, or significant liver enzyme increase
- Need for systemic corticosteroids or other immunosuppressive drugs within 14 days before enrollment
- Serious infection within 4 weeks before enrollment, including hospitalization due to infection
- Severe chronic or active infections requiring systemic antibiotic therapy within 14 days before enrollment
- Untreated chronic hepatitis B with HBV DNA 2500 IU/mL, active hepatitis C, or known HIV infection
- Participation in other clinical trials or investigational drug treatment within 28 days prior
- Contraindications to stereotactic radiotherapy or immune checkpoint inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
the second affiliated hospital of Army medical university
Chongqing, Chongqing Municipality, China, 40037
Actively Recruiting
2
Jianguo Sun
Chongqing, China, 400000
Not Yet Recruiting
Research Team
J
Jianguo Sun, doctor
CONTACT
L
Lin-Peng Zheng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here